<html>
<head>
<style type="text/css">
.inline {
  background-color: #f7f7f7;
  border:solid 1px #B0B0B0;
}
.error {
	font-weight: bold;
	color: #FF0000;
}
.warning {
	font-weight: bold;
}
.message {
	font-style: italic;
}
.source, .output, .warning, .error, .message {
	padding: 0 1em;
  border:solid 1px #F7F7F7;
}
.source {
  background-color: #f5f5f5;
}
.left {
  text-align: left;
}
.right {
  text-align: right;
}
.center {
  text-align: center;
}
.hl.num {
  color: #AF0F91;
}
.hl.str {
  color: #317ECC;
}
.hl.com {
  color: #AD95AF;
  font-style: italic;
}
.hl.opt {
  color: #000000;
}
.hl.std {
  color: #585858;
}
.hl.kwa {
  color: #295F94;
  font-weight: bold;
}
.hl.kwb {
  color: #B05A65;
}
.hl.kwc {
  color: #55aa55;
}
.hl.kwd {
  color: #BC5A65;
  font-weight: bold;
}
</style>
  <link rel="stylesheet" href="code/www/custom.css">
</head>
 <table style="width:70%; color: #2d5973;" align = "center">
  <tr style="border-bottom:3px solid #2daed8;background-color: #f7f7f7;">
    <td style="width:10%"></td>
    <td style="border-left:3px solid #2daed8;width:25%"><spam style="font-size:22px;"><b>Low Impact Variant</b></spam><spam style="font-size:20px;"></br>(low transmissibility increase, no immune escape)</spam></td>
    <td style="border-left:3px solid #bfbfbf;width:25%"><spam style="font-size:22px;"><b>High Impact Variant</b></spam><spam style="font-size:20px;"></br>(high transmissibility increase, no immune escape)</spam></td>
  </tr>
  <tr>
    <td valign="top" style="border-right:3px solid #2daed8;background-color: #f7f7f7;border-bottom:3px solid #bfbfbf">
      <spam style="font-size:22px;"><b>High Vaccination</b></spam></br><spam style="font-size:20px;">(low hesistancy)</spam></td>
    <td style="background-color: #fdfdfd;width:300px;border-bottom:3px solid #bfbfbf">
      <spam style="font-size:22px;color:#2daed8;" class="right"><b>Scenario A</b></spam></br>
      <spam class="left" style="font-size:20px;"><b>Vaccination</b></spam></br>
      <spam class="left" style="font-size:18px;">- Coverage saturates at <b>86% nationally</b> among the vaccine-eligible population* by November 30, 2021**</br>
        - VE is <b>50%/90%</b> for Pfizer/Moderna against currently circulating variants (1st/2nd dose)</br>
        - J&J no longer used</br> </br></spam>
      <hr style="border: 0.5px solid;border-color: #E4E4E4;margin-left:20px;margin-right:20px;margin-top:50px;">
      <spam style="font-size:20px;"><b>Variant</b></spam>
      <div style="font-size:18px;"><b>20% increased transmissibility</b> as compared by B.1.1.7 for B.1.617+ variant. <b>5%</b> prevalence of B.1.617+ nationally on May 29.</div></br>
    </td>
    <td style="border-left:3px solid #bfbfbf;background-color: #fdfdfd;border-bottom:3px solid #bfbfbf">
      <spam style="font-size:22px;color:#2daed8;" class="right"><b>Scenario B</b></spam></br>
      <spam class="left" style="font-size:20px;"><b>Vaccination</b></spam></br>
      <spam class="left" style="font-size:18px;">- Coverage saturates at <b>86% nationally</b> among the vaccine-eligible population* by November 30, 2021**</br>
        - VE is <b>50%/90%</b> for Pfizer/Moderna against currently circulating variants (1st/2nd dose)</br>
        - J&J no longer used</br> </br></spam>
      <hr style="border: 0.5px solid;border-color: #E4E4E4;margin-left:20px;margin-right:20px;margin-top:50px;">
      <spam style="font-size:20px;"><b>Variant</b></spam>
      <div style="font-size:18px;"><b>60% increased transmissibility</b> as compared by B.1.1.7 for B.1.617+ variant. <b>5%</b> prevalence of B.1.617+ nationally on May 29.</div></br>
    </td>
  </tr>
  <tr>
    <td valign="top" style="border-right:3px solid #2daed8;background-color: #f7f7f7;">
      <spam style="font-size:22px;"><b>Low Vaccination</b></spam><spam style="font-size:20px;"></br>(high hesistancy)</spam></td>
    <td style="background-color: #fdfdfd;">
     <spam style="font-size:22px;color:#2daed8;" class="right"><b>Scenario C</b></spam></br>
     <spam class="left" style="font-size:20px;"><b>Vaccination</b></spam></br>
     <spam class="left" style="font-size:18px;">- Coverage saturates at <b>75% nationally</b> among the vaccine-eligible population* by November 30, 2021**</br>
        - VE is <b>50%/90%</b> for Pfizer/Moderna against currently circulating variants (1st/2nd dose) and 60% for JJ (1 dose)</br>
        - J&J no longer used</br> </br></spam>
     <hr style="border: 0.5px solid;border-color: #E4E4E4;margin-left:20px;margin-right:20px;margin-top:50px;">
     <spam style="font-size:20px;"><b>Variant</b></spam>
     <div style="font-size:18px;"><b>20% increased transmissibility</b> as compared by B.1.1.7 for B.1.617+ variant. <b>5%</b> prevalence of B.1.617+ nationally on May 29.</div></br>
    </td>
    <td style="border-left:3px solid #bfbfbf;background-color: #fdfdfd;">
     <spam style="font-size:22px;color:#2daed8;" class="right"><b>Scenario D</b></spam></br>
     <spam class="left" style="font-size:20px;"><b>Vaccination</b></spam></br>
     <spam class="left" style="font-size:18px;">- Coverage saturates at <b>75% nationally</b> among the vaccine-eligible population* by November 30, 2021**</br>
        - VE is <b>50%/90%</b> for Pfizer/Moderna against currently circulating variants (1st/2nd dose) and 60% for JJ (1 dose)</br>
        - J&J no longer used</br> </br></spam>
     <hr style="border: 0.5px solid;border-color: #E4E4E4;margin-left:20px;margin-right:20px;margin-top:50px;">
     <spam style="font-size:20px;"><b>Variant</b></spam>
     <div style="font-size:18px;"><b>60% increased transmissibility</b> as compared by B.1.1.7 for B.1.617+ variant. <b>5%</b> prevalence of B.1.617+ nationally on May 29.</div></br>
    </td>
  </tr>
</table> 
<hr style="border-top:1.5px dotted #bfbfbf;margin-left:15%;margin-right:15%;margin-top:50px">
</br>
<div style="font-size:18px;margin-left:15%;margin-right:15%;color: #2d5973"> * <b>Vaccine-eligible population.</b> The eligible population for vaccination is presumed to be individuals aged 16 years or older until May 12, 2021. On May 12, the eligible population is extended to individuals aged 12 years and older, through the end of the projection period. </br></br>
** <b>Vaccine hesitancy</b> expected to cause vaccination coverage to slow and eventually saturate at some level below 100%. The saturation levels provided in these scenarios are National reference points to guide defining hesitancy, though the speed of that saturation and heterogeneity between states (or other geospatial scales) and/or age groups are at the discretion of the modeling team. The high vaccination 86% saturation is defined using the current estimates from the Delphi group (<a href="https://delphi.cmu.edu/covidcast/indicator/?date=20210313&sensor=fb-survey-smoothed_covid_vaccinated_or_accept">link</a>, updated from Round 5). The low saturation estimate of 75% is the lowest county-level estimate from the U.S. Census Bureauâ€™s Pulse Survey from Apr 14-26, 2021 data (<a href="https://data.cdc.gov/stories/s/Vaccine-Hesitancy-for-COVID-19/cnd2-a6zw">link</a>), which is updated from Round 5</div>
</html>
